Open Trials

Ovary

AGO-OVAR 27

Window-of-opportunity proof-of-concept, non-randomized, open-label phase II trial of Olaparib given alone (cohort A) or in combination with Durvalumab (cohort B) prior to primary debulking surgery in histologically proven high-grade epithelial ovarian cancer (EOC)

WoO: Window of Opportunity trial of Olaparib and Durvalumab in histologically proven EOC

AGO-OVAR 28

Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial)

 

AGO-OVAR 2.34 / MIROVA

A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy

Ovary / Endometrium / Cervix

AGO-ZX 4

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin versus Investigator’s  Choice Chemotherapy in Second or Third Line Recurrent or Metastatic Cervical Cancer

Surgical issues

AGO-OVAR OP.6 ECLAT

Pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer at high risk of recurrence. A multicenter, prospective randomized controlled trial.

AGO-OVAR OP.9 SENTICOL III

International validation study of sentinel node biopsy in early cervical cancer